Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Gyre Therapeutics (GYRE) over the last 7 years, with Q3 2025 value amounting to $15.3 million.

  • Gyre Therapeutics' Cost of Revenue rose 1189.14% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.2 million, marking a year-over-year increase of 192.58%. This contributed to the annual value of $57.5 million for FY2024, which is 596.48% down from last year.
  • Per Gyre Therapeutics' latest filing, its Cost of Revenue stood at $15.3 million for Q3 2025, which was up 1189.14% from $15.2 million recorded in Q2 2025.
  • Gyre Therapeutics' Cost of Revenue's 5-year high stood at $53.4 million during Q4 2022, with a 5-year trough of $798000.0 in Q1 2022.
  • In the last 5 years, Gyre Therapeutics' Cost of Revenue had a median value of $13.7 million in 2024 and averaged $13.0 million.
  • In the last 5 years, Gyre Therapeutics' Cost of Revenue surged by 207766.91% in 2022 and then plummeted by 6919.16% in 2023.
  • Gyre Therapeutics' Cost of Revenue (Quarter) stood at $2.5 million in 2021, then soared by 2077.67% to $53.4 million in 2022, then plummeted by 69.19% to $16.5 million in 2023, then grew by 2.38% to $16.9 million in 2024, then dropped by 9.07% to $15.3 million in 2025.
  • Its Cost of Revenue stands at $15.3 million for Q3 2025, versus $15.2 million for Q2 2025 and $10.8 million for Q1 2025.